Literature DB >> 20845516

Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis.

Chun Gao1, Hong-Chuan Zhao, Jing-Tao Li, Shu-Kun Yao.   

Abstract

AIM: To determine the role of diabetes mellitus (DM) and other associated factors in Chinese hepatocellular carcinoma (HCC) patients with cirrhosis, compared with those HCC patients without cirrhosis, in the single setting of hepatitis B virus (HBV) infection, after other known concomitant diseases were excluded.
METHODS: A total of 482 patients, treated at the China-Japan Friendship Hospital, Ministry of Health (Beijing, China), in the period January 2003 to June 2009, and with a hospital discharge diagnosis of HCC, were included. Demographic, clinical, laboratory, metabolic and instrumental features were analyzed.
RESULTS: Of the total, 310 patients were diagnosed with HBV infection and, following the inclusion and exclusion criteria, 224 were analyzed, including 122 patients (54.5%) with cirrhosis (the case group) and 102 patients without cirrhosis (the control group). Twenty-seven patients (12.1%) were diabetic, including 19 in the case group and 8 in the control group (19/122 = 15.6% vs 8/102 = 7.8%, P = 0.077). Thirty-one possible relevant parameters were compared by univariate analysis, and 9 variables were selected for multivariable analysis, including DM (P = 0.077), past history of HBV infection (P = 0.005), total bilirubin (P < 0.001), albumin level (P < 0.001), international normalized ratio (INR) (P < 0.001), alanine aminotransferase (P = 0.050), platelet (P < 0.001), total cholesterol (P = 0.047), and LDL cholesterol (P = 0.002) levels. Diabetes showed a statistical difference by multivariable analysis [odds ratio (OR) 4.88, 95% confidence interval (CI): 1.08-21.99, P = 0.039], although no significant difference was found in univariate analysis. In addition, three cirrhosis-related parameters remained statistically different, including INR (OR 117.14, 95% CI: 4.19-3272.28, P = 0.005), albumin (OR 0.89, 95% CI: 0.80-0.99, P = 0.027), and platelet count (OR 0.992, 95% CI: 0.987-0.999, P = 0.002).
CONCLUSION: Besides the three cirrhosis-related parameters, DM was found to be the sole independent factor associated with HCC in patients with HBV-related cirrhosis, compared with those without cirrhosis.

Entities:  

Mesh:

Year:  2010        PMID: 20845516      PMCID: PMC2941072          DOI: 10.3748/wjg.v16.i35.4467

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?

Authors:  H P Cotrim; R Paraná; E Braga; L Lyra
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

2.  Cancer mortality among diabetics.

Authors:  I I Kessler
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

3.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

4.  Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma.

Authors:  H Toyoda; T Kumada; S Nakano; I Takeda; K Sugiyama; S Kiriyama; M Tanikawa; Y Sone; Y Hisanaga
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

5.  The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans.

Authors:  H B El-Serag; P A Richardson; J E Everhart
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

6.  Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies.

Authors:  Hung-Da Tung; Jing-Houng Wang; Po-Lin Tseng; Chao-Hung Hung; Kwong-Ming Kee; Chien-Hung Chen; Kuo-Chin Chang; Chuan-Mo Lee; Chi-Sin Changchien; Yao-Der Chen; Sheng-Nan Lu
Journal:  Am J Gastroenterol       Date:  2010-01-05       Impact factor: 10.864

7.  Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

Authors:  Masahiko Shimada; Etsuko Hashimoto; Makiko Taniai; Kiyoshi Hasegawa; Hiroaki Okuda; Naoaki Hayashi; Ken Takasaki; Jurgen Ludwig
Journal:  J Hepatol       Date:  2002-07       Impact factor: 25.083

Review 8.  Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma?

Authors:  Chun Gao; Shu-Kun Yao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2009-10

9.  Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Yasuyo Morita; Miki Shirachi; Ikuo Tateishi; Eisuke Nagata; Michio Sata
Journal:  Liver Int       Date:  2009-12-22       Impact factor: 5.828

10.  Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.

Authors:  Manal M Hassan; Lu-Yu Hwang; Chiq J Hatten; Mark Swaim; Donghui Li; James L Abbruzzese; Palmer Beasley; Yehuda Z Patt
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

View more
  13 in total

1.  Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA.

Authors:  Neehar D Parikh; Sherry Fu; Huiying Rao; Ming Yang; Yumeng Li; Corey Powell; Elizabeth Wu; Andy Lin; Baocai Xing; Lai Wei; Anna S F Lok
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

2.  Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012.

Authors:  Keisuke Amano; Takumi Kawaguchi; Ryoko Kuromatsu; Atsushi Kawaguchi; Ichiro Miyajima; Tatsuya Ide; Tatsuyuki Kakuma; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-08-21

3.  Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus.

Authors:  Hui Zhang; Chun Gao; Long Fang; Shu-Kun Yao
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

4.  Significance and prognostic value of increased serum direct bilirubin level for lymph node metastasis in Chinese rectal cancer patients.

Authors:  Chun Gao; Long Fang; Jing-Tao Li; Hong-Chuan Zhao
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

5.  Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection.

Authors:  Axel Hsu; Ching-Lung Lai; Man-Fung Yuen
Journal:  Curr Hepat Rep       Date:  2011-02-19

Review 6.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

7.  High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia.

Authors:  Chien-Yuan Chen; Sheng-Yi Huang; Aristine Cheng; Wen-Chien Chou; Ming Yao; Jih-Luh Tang; Woei Tsay; Wang-Huei Sheng; Hwei-Fang Tien
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 8.  HBV induced HCC: major risk factors from genetic to molecular level.

Authors:  Ambreen Ayub; Usman Ali Ashfaq; Asma Haque
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

9.  The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.

Authors:  Yuan-Hung Kuo; Sheng-Nan Lu; Chien-Hung Chen; Kuo-Chin Chang; Chao-Hung Hung; Wei-Chen Tai; Ming-Chao Tsai; Po-Lin Tseng; Tsung-Hui Hu; Jing-Houng Wang
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

Review 10.  Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Yan-Gang Wang; Peng Wang; Bin Wang; Zheng-Ju Fu; Wen-Juan Zhao; Sheng-Li Yan
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.